Refining the prognostic impact of functional mitral regurgitation in chronic heart failure

European Heart Journal

Volumn 39, Issue 1, 2018, Pages 39-46

  Goliasch, Georg ^a   Bartko, Philipp E ^a   Pavo, Noemi ^a   Neuhold, Stephanie ^b   Wurm, Raphael ^a   Mascherbauer, Julia ^a   Lang, Irene M ^a   Strunk, Guido ^c   Hülsmann, Martin ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b KAISER FRANZ JOSEF HOSPITAL   (Austria)

^c Fachhochschule Campus Wien   (Austria)

Author keywords

Functional mitral regurgitation; Hfref; Prognosis

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; AMIODARONE; ATRIAL NATRIURETIC FACTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; COPEPTIN; ENDOTHELIN 1; FUROSEMIDE; MINERALOCORTICOID ANTAGONIST;

ADULT; ARTICLE; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOVASCULAR MORTALITY; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE SEVERITY; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART FAILURE WITH REDUCED EJECTION FRACTION; HEART HEMODYNAMICS; HEART LEFT VENTRICLE FUNCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MITRAL VALVE REGURGITATION; NEW YORK HEART ASSOCIATION CLASS; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSTIC ASSESSMENT; PROSPECTIVE STUDY; AGED; CHRONIC DISEASE; COMPLICATION; HEART FAILURE; HEART STROKE VOLUME; HEMODYNAMICS; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; PROGNOSIS;

AGED; CHRONIC DISEASE; FEMALE; HEART FAILURE; HEMODYNAMICS; HUMANS; MALE; MIDDLE AGED; MITRAL VALVE INSUFFICIENCY; PROGNOSIS; STROKE VOLUME;

EID: 85040691642     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehx402     Document Type: Article

References (30)

1. Rossi A, Dini FL, Faggiano P, Agricola E, Cicoira M, Frattini S, Simioniuc A, Gullace M, Ghio S, Enriquez-Sarano M, Temporelli PL. Independent prognostic value of functional mitral regurgitation in patients with heart failure. A quantitative analysis of 1256 patients with ischaemic and non-ischaemic dilated cardiomyopathy. Heart 2011;97:1675-1680
2. Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC); European Association for Cardio-Thoracic Surgery (EACTS), Vahanian A, Alfieri O, Andreotti F, Antunes MJ, Baron-Esquivias G, Baumgartner H, Borger MA, Carrel TP, Bonis M. D , Evangelista A, Falk V, Iung B, Lancellotti P, Pierard L, Price S, Schafers HJ, Schuler G, Stepinska J, Swedberg K, Takkenberg J, Von Oppell UO, Windecker S, Zamorano JL, Zembala M. Guidelines on the management of valvular heart disease (version 2012). Eur Heart J 2012;33:2451-2496
3. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P; Authors/Task Force Members. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016;37:2129-2200
4. Nishimura RA, Vahanian A, Eleid MF, Mack MJ. Mitral valve disease-current management and future challenges. Lancet 2016;387:1324-1334
5. Beaudoin J, Levine RA, Guerrero JL, Yosefy C, Sullivan S, Abedat S, Handschumacher MD, Szymanski C, Gilon D, Palmeri NO, Vlahakes GJ, Hajjar RJ, Beeri R. Late repair of ischemic mitral regurgitation does not prevent left ventricular remodeling: importance of timing for beneficial repair. Circulation 2013; 128:S248-S252
6. Beeri R, Yosefy C, Guerrero JL, Nesta F, Abedat S, Chaput M, del Monte F, Handschumacher MD, Stroud R, Sullivan S, Pugatsch T, Gilon D, Vlahakes GJ, Spinale FG, Hajjar RJ, Levine RA. Mitral regurgitation augments post-myocardial infarction remodeling failure of hypertrophic compensation. J Am Coll Cardiol 2008;51:476-486
7. Grigioni F, Enriquez-Sarano M, Zehr KJ, Bailey KR, Tajik AJ. Ischemic mitral regurgitation: long-Term outcome and prognostic implications with quantitative Doppler assessment. Circulation 2001;103:1759-1764
8. Nickenig G, Schueler R, Dager A, Martinez Clark P, Abizaid A, Siminiak T, Buszman P, Demkow M, Ebner A, Asch FM, Hammerstingl C. Treatment of chronic functional mitral valve regurgitation with a percutaneous annuloplasty system. J Am Coll Cardiol 2016;67:2927-2936
9. De Bonis M, Al-Attar N, Antunes M, Borger M, Casselman F, Falk V, Folliguet T, Iung B, Lancellotti P, Lentini S, Maisano F, Messika-Zeitoun D, Muneretto C, Pibarot P, Pierard L, Punjabi P, Rosenhek R, Suwalski P, Vahanian A, Wendler O, Prendergast B. Surgical and interventional management of mitral valve regurgitation: A position statement from the European Society of Cardiology Working Groups on Cardiovascular Surgery and Valvular Heart Disease. Eur Heart J 2016;37:133-139
10. Neuhold S, Huelsmann M, Strunk G, Stoiser B, Struck J, Morgenthaler NG, Bergmann A, Moertl D, Berger R, Pacher R. Comparison of copeptin, B-Type natriuretic peptide, and amino-Terminal pro-B-Type natriuretic peptide in patients with chronic heart failure: prediction of death at different stages of the disease. J Am Coll Cardiol 2008;52:266-272
11. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, Cooney MT, Corra U, Cosyns B, Deaton C, Graham I, Hall MS, Hobbs FD, Lochen ML, Lollgen H, Marques-Vidal P, Perk J, Prescott E, Redon J, Richter DJ, Sattar N, Smulders Y, Tiberi M, van der Worp HB, van Dis I, Verschuren WM; Authors/Task Force Members. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2016;37:2315-2381
12. Wiesbauer F, Baytaroglu C, Azar D, Blessberger H, Goliasch G, Graf S, Mundigler G, Pacher R, Maurer G, Binder T. Echo Doppler parameters predict response to cardiac resynchronization therapy. Eur J Clin Invest 2009;39:1-10
13. Kazemi-Shirazi L, Endler G, Winkler S, Schickbauer T, Wagner O, Marsik C. Gamma glutamyltransferase and long-Term survival: is it just the liver? Clin Chem 2007;53:940-946
14. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise J, Solomon S, Spencer KT, St John Sutton M, Stewart W; American Society of Echocardiography?s Nomenclature and Standards Committee; Task Force on Chamber Quantification; American College of Cardiology Echocardiography Committee; American Heart Association; European Association of Echocardiography, European Society of Cardiology. Recommendations for chamber quantification. Eur J Echocardiogr 2006;7:79-108
15. Baumgartner HC, Hung JC-C, Bermejo J, Chambers JB, Edvardsen T, Goldstein S, Lancellotti P, LeFevre M, Miller F Jr, Otto CM. Recommendations on the echocardiographic assessment of aortic valve stenosis: A focused update from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. Eur Heart J Cardiovasc Imaging 2017;18:254-275
16. Lancellotti P, Tribouilloy C, Hagendorff A, Popescu BA, Edvardsen T, Pierard LA, Badano L, Zamorano JL; Scientific Document Committee of the European Association of Cardiovascular Imaging. Recommendations for the echocardiographic assessment of native valvular regurgitation: An executive summary from the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2013;14:611-644
17. Adlbrecht C, Hulsmann M, Strunk G, Berger R, Mortl D, Struck J, Morgenthaler NG, Bergmann A, Jakowitsch J, Maurer G, Lang IM, Pacher R. Prognostic value of plasma midregional pro-Adrenomedullin and C-Terminal-pro-endothelin-1 in chronic heart failure outpatients. Eur J Heart Fail 2009;11:361-366
18. Klaar U, Gabriel H, Bergler-Klein J, Pernicka E, Heger M, Mascherbauer J, Rosenhek R, Binder T, Maurer G, Baumgartner H. Prognostic value of serial B-Type natriuretic peptide measurement in asymptomatic organic mitral regurgitation. Eur J Heart Fail 2011;13:163-169
19. Daniels LB, Clopton P, Potocki M, Mueller C, McCord J, Richards M, Hartmann O, Anand IS, Wu AH, Nowak R, Peacock WF, Ponikowski P, Mockel M, Hogan C, Filippatos GS, Di Somma S, Ng L, Neath SX, Christenson R, Morgenthaler NG, Anker SD, Maisel AS. Influence of age, race, sex, and body mass index on interpretation of midregional pro atrial natriuretic peptide for the diagnosis of acute heart failure: results from the BACH multinational study. Eur J Heart Fail 2012;14:22-31
20. Shah RV, Truong QA, Gaggin HK, Pfannkuche J, Hartmann O, Januzzi JL Jr. Midregional pro-Atrial natriuretic peptide and pro-Adrenomedullin testing for the diagnostic and prognostic evaluation of patients with acute dyspnoea. Eur Heart J 2012;33:2197-2205
21. Mayyas F, Niebauer M, Zurick A, Barnard J, Gillinov AM, Chung MK, Van Wagoner DR. Association of left atrial endothelin-1 with atrial rhythm, size, and fibrosis in patients with structural heart disease. Circ Arrhythm Electrophysiol 2010; 3:369-379
22. Weiner RB, Baggish AL, Chen-Tournoux A, Marshall JE, Gaggin HK, Bhardwaj A, Mohammed AA, Rehman SU, Barajas L, Barajas J, Gregory SA, Moore SA, Semigran MJ, Januzzi JL Jr. Improvement in structural and functional echocardiographic parameters during chronic heart failure therapy guided by natriuretic peptides: mechanistic insights from the ProBNP Outpatient Tailored Chronic Heart Failure (PROTECT) study. Eur J Heart Fail 2013;15:342-351
23. Ellis SG, Whitlow PL, Raymond RE, Schneider JP. Impact of mitral regurgitation on long-Term survival after percutaneous coronary intervention. Am J Cardiol 2002;89:315-318
24. Grigioni F, Detaint D, Avierinos JF, Scott C, Tajik J, Enriquez-Sarano M. Contribution of ischemic mitral regurgitation to congestive heart failure after myocardial infarction. J Am Coll Cardiol 2005;45:260-267
25. Lamas GA, Mitchell GF, Flaker GC, Smith SC Jr, Gersh BJ, Basta L, Moye L, Braunwald E, Pfeffer MA; Survival and Ventricular Enlargement Investigators. Clinical significance of mitral regurgitation after acute myocardial infarction. Circulation 1997;96:827-833
26. Maisano F, Franzen O, Baldus S, Schafer U, Hausleiter J, Butter C, Ussia GP, Sievert H, Richardt G, Widder JD, Moccetti T, Schillinger W. Percutaneous mitral valve interventions in the real world: early and 1-year results from the ACCESS-EU, a prospective, multicenter, nonrandomized post-Approval study of the MitraClip therapy in Europe. J Am Coll Cardiol 2013;62:1052-1061
27. Puls M, Lubos E, Boekstegers P, von Bardeleben RS, Ouarrak T, Butter C, Zuern CS, Bekeredjian R, Sievert H, Nickenig G, Eggebrecht H, Senges J, Schillinger W. One-year outcomes and predictors of mortality after MitraClip therapy in contemporary clinical practice: results from the German transcatheter mitral valve interventions registry. Eur Heart J 2016;37:703-712
28. Packer M. Heart failure?s dark secret: does anyone really care about optimal medical therapy? Circulation 2016;134:629-631
29. Feldman T, Foster E, Glower DD, Kar S, Rinaldi MJ, Fail PS, Smalling RW, Siegel R, Rose GA, Engeron E, Loghin C, Trento A, Skipper ER, Fudge T, Letsou GV, Massaro JM, Mauri L, Investigators EI. Percutaneous repair or surgery for mitral regurgitation. N Engl J Med 2011;364:1395-1406
30. Feldman T, Kar S, Elmariah S, Smart SC, Trento A, Siegel RJ, Apruzzese P, Fail P, Rinaldi MJ, Smalling RW, Hermiller JB, Heimansohn D, Gray WA, Grayburn PA, Mack MJ, Lim DS, Ailawadi G, Herrmann HC, Acker MA, Silvestry FE, Foster E, Wang A, Glower DD, Mauri L, Investigators EI. Randomized comparison of percutaneous repair and surgery for mitral regurgitation: 5-year results of EVEREST II. J Am Coll Cardiol 2015;66:2844-2854.